[ad_1]
Blueprint Medicines BPMC reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM.
Here’s what investors need to know about the announcement.
Earnings
Blueprint Medicines missed estimated earnings by 20.18%, reporting an EPS of $-2.68 versus an estimate of $-2.23.
Revenue was up $9.25 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.15 which was followed by a 0.7% increase in the share price the next day.
Here’s a look at Blueprint Medicines’s past performance:
Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
---|---|---|---|---|
EPS Estimate | -1.94 | -1.65 | -1.63 | -1.86 |
EPS Actual | -1.79 | -0.99 | -2 | -1.86 |
Revenue Estimate | 36.65M | 102.69M | 42.47M | 19.01M |
Revenue Actual | 62.73M | 107.02M | 24.19M | 27.30M |
To track all earnings releases for Blueprint Medicines visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
[ad_2]
Image and article originally from www.benzinga.com. Read the original article here.